Infant Exposure to Dolutegravir Through Placental and Breast Milk Transfer: A Population Pharmacokinetic Analysis of DolPHIN-1

Autor: Dickinson, Laura, Walimbwa, Stephen, Singh, Yashna, Kaboggoza, Julian, Kintu, Kenneth, Sihlangu, Mary, Coombs, Julie-Anne, Malaba, Thokozile R, Byamugisha, Josaphat, Pertinez, Henry, Amara, Alieu, Gini, Joshua, Else, Laura, Heiberg, Christie, Hodel, Eva Maria, Reynolds, Helen, Myer, Landon, Waitt, Catriona, Khoo, Saye, Lamorde, Mohammed, Orrell, Catherine, Grp, DolPHIN-1 Study

Publikováno v: CLINICAL INFECTIOUS DISEASES
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America

Background Rapid reduction in human immunodeficiency virus (HIV) load is paramount to prevent peripartum transmission in women diagnosed late in pregnancy. We investigated dolutegravir population pharmacokinetics in maternal plasma, umbilical cord, b

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8962bb51ff3eac4f137770c2614a2be0

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Infant Exposure to Dolutegravir Through Placental and Breast Milk Transfer: A Population Pharmacokinetic Analysis of DolPHIN-1.

Autor: Dickinson L; Department of Molecular & Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom., Walimbwa S; Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda., Singh Y; Desmond Tutu HIV Foundation, University of Cape Town, Cape Town, South Africa., Kaboggoza J; Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda., Kintu K; Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda., Sihlangu M; Desmond Tutu HIV Foundation, University of Cape Town, Cape Town, South Africa., Coombs JA; Desmond Tutu HIV Foundation, University of Cape Town, Cape Town, South Africa., Malaba TR; Division of Epidemiology & Biostatistics, School of Public Health & Family Medicine, University of Cape Town, Cape Town, South Africa., Byamugisha J; Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda., Pertinez H; Department of Molecular & Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom., Amara A; Department of Molecular & Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom., Gini J; Department of Molecular & Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom., Else L; Department of Molecular & Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom., Heiberg C; Desmond Tutu HIV Foundation, University of Cape Town, Cape Town, South Africa., Hodel EM; Department of Molecular & Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom., Reynolds H; Department of Molecular & Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom., Myer L; Division of Epidemiology & Biostatistics, School of Public Health & Family Medicine, University of Cape Town, Cape Town, South Africa., Waitt C; Department of Molecular & Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom., Khoo S; Department of Molecular & Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom., Lamorde M; Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda., Orrell C; Desmond Tutu HIV Foundation, University of Cape Town, Cape Town, South Africa.

Publikováno v: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2021 Sep 07; Vol. 73 (5), pp. e1200-e1207.